60 related articles for article (PubMed ID: 17302247)
1. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Kuntzen T; Timm J; Berical A; Lennon N; Berlin AM; Young SK; Lee B; Heckerman D; Carlson J; Reyor LL; Kleyman M; McMahon CM; Birch C; Schulze Zur Wiesch J; Ledlie T; Koehrsen M; Kodira C; Roberts AD; Lauer GM; Rosen HR; Bihl F; Cerny A; Spengler U; Liu Z; Kim AY; Xing Y; Schneidewind A; Madey MA; Fleckenstein JF; Park VM; Galagan JE; Nusbaum C; Walker BD; Lake-Bakaar GV; Daar ES; Jacobson IM; Gomperts ED; Edlin BR; Donfield SM; Chung RT; Talal AH; Marion T; Birren BW; Henn MR; Allen TM
Hepatology; 2008 Dec; 48(6):1769-78. PubMed ID: 19026009
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.
Soumana DI; Kurt Yilmaz N; Ali A; Prachanronarong KL; Schiffer CA
J Am Chem Soc; 2016 Sep; 138(36):11850-9. PubMed ID: 27512818
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insights.
Shahab M; Khan A; Khan SA; Zheng G
Int J Biol Macromol; 2024 May; 267(Pt 2):131629. PubMed ID: 38631585
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
Bu G; Danelius E; Wieske LHE; Gonen T
Adv Biol (Weinh); 2024 May; 8(5):e2300570. PubMed ID: 38381052
[TBL] [Abstract][Full Text] [Related]
6. Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.
Cheng KC; Korfmacher WA; White RE; Njoroge FG
Perspect Medicin Chem; 2007 Jun; 1():1-9. PubMed ID: 19812732
[TBL] [Abstract][Full Text] [Related]
7. Update on hepatitis C virus resistance to direct-acting antiviral agents.
Poveda E; Wyles DL; Mena A; Pedreira JD; Castro-Iglesias A; Cachay E
Antiviral Res; 2014 Aug; 108():181-91. PubMed ID: 24911972
[TBL] [Abstract][Full Text] [Related]
8. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.
Izhari MA
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835845
[TBL] [Abstract][Full Text] [Related]
10. Janus Dendrimers to Assess the Anti-HCV Activity of Molecules in Cell-Assays.
San Anselmo M; Lancelot A; Egido JE; Clavería-Gimeno R; Casanova Á; Serrano JL; Hernández-Ainsa S; Abian O; Sierra T
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33171841
[TBL] [Abstract][Full Text] [Related]
11. Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant.
Meewan I; Zhang X; Roy S; Ballatore C; O'Donoghue AJ; Schooley RT; Abagyan R
ACS Omega; 2019 Oct; 4(16):16999-17008. PubMed ID: 31646247
[TBL] [Abstract][Full Text] [Related]
12. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran.
Afrasiabi M; Hosseini SY; Yaghobi R; Fattahi MR; Ardebili M; Khodadad M
Jundishapur J Microbiol; 2015 Oct; 8(10):e24965. PubMed ID: 26587218
[TBL] [Abstract][Full Text] [Related]
14. Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.
Claveria-Gimeno R; Vega S; Grazu V; de la Fuente JM; Lanas A; Velazquez-Campoy A; Abian O
Int J Nanomedicine; 2015; 10():2249-59. PubMed ID: 25834436
[TBL] [Abstract][Full Text] [Related]
15. The skill and style to model the evolution of resistance to pesticides and drugs.
REX Consortium
Evol Appl; 2010 Jul; 3(4):375-90. PubMed ID: 25567932
[TBL] [Abstract][Full Text] [Related]
16. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.
El-Shamy A; Hotta H
World J Gastroenterol; 2014 Jun; 20(24):7555-69. PubMed ID: 24976696
[TBL] [Abstract][Full Text] [Related]
17. Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1' Region.
Lampa AK; Bergman SM; Gustafsson SS; Alogheli H; Akerblom EB; Lindeberg GG; Svensson RM; Artursson P; Danielson UH; Karlén A; Sandström A
ACS Med Chem Lett; 2014 Mar; 5(3):249-54. PubMed ID: 24900813
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibitors of the NS3 protease from the hepatitis C virus.
Abian O; Vega S; Sancho J; Velazquez-Campoy A
PLoS One; 2013; 8(7):e69773. PubMed ID: 23936097
[TBL] [Abstract][Full Text] [Related]
19. NS3 protease from hepatitis C virus: biophysical studies on an intrinsically disordered protein domain.
Vega S; Neira JL; Marcuello C; Lostao A; Abian O; Velazquez-Campoy A
Int J Mol Sci; 2013 Jun; 14(7):13282-306. PubMed ID: 23803659
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
